Senetek PLC (Senetek) is a life sciences company engaged in the development of technologies that target the science of healthy aging. The Company’s business consists of two business segments: dermatological/skincare compounds principally addressing photoaging and other skincare needs (Skincare), and pharmaceuticals, principally those addressing sales of monoclonal antibodies, sexual dysfunction and drug delivery of liquid injectable products (automatic injectors) (Pharmaceutical). The Skincare segment’s products include Pyratine-6, 4HBAP and Kinetin. The Pharmaceutical segment’s products include Invicorp, Reliaject, and diagnostic monoclonal antibodies used in Alzheimer’s and other disease research, which the Company licenses from Research Foundation for Mental Hygiene (RFMH) and sells to Covance Antibody Services Inc. The Company has three wholly owned subsidiaries, Senetek Drug Delivery Technologies Inc. (SSDT), Carme Cosmeceutical Sciences Inc. (CCSI) and Senetek Denmark ApS.

Lab901 is not that college class you flunked. It's a company that develops and manufactures laboratory processing products to increase the efficiency of analytical laboratory testing used for DNA tests and other applications. Lab901's ScreenTape system is disposable a credit-card sized strip patterned with reagents used to process and analyze biological samples such as blood, DNA, and RNA. Lab901 was formed in 2001.

Santhera Pharmaceuticals Holding AG (Santhera) is a Swiss company focused on discovery, development and commercialization of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases. CATENA is Santhera’s first product approved in Canada for symptomatic treatment of Friedreich's ataxia. Santhera has five clinical-stage development programs, three of which investigate its core compound, SNT-MC17/idebenon, in the treatment of Friedreich’s ataxia, Duchenne muscular dystrophy and Leber’s hereditary optic neuropathy. Another clinical program investigates JP-1730/fipamezole in the treatment of dyskinesia in Parkinson’s disease. The fifth program concerns congenital muscular dystrophies. It operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, engaged in research and development of pharmaceuticals, Santhera Pharmaceuticals (Canada), Inc., active in marketing and sales of pharmaceuticals, and Santhera Pharmaceuticals (USA), Inc.

Kalypsys is searching for new medicines, and has developed a zippy way to find them. Its ultra-high throughput automated epiK screening system can analyze more than one million cell-based assay wells a day and can run 24 hours a day seven days a week. With that kind of research capability, the company has developed its own bioinformatics software to enable researchers to quickly find and compare data points. Kalypsys is generous enough to market the system, under the Kalypsys Systems brand, to other pharmaceutical research facilities. Its own drug development pipeline includes compounds in early stages of development, targeting cancer, inflammatory diseases, pain, and metabolic diseases.

454 Life Sciences company has developed a computer-controlled instrument and related software that enable scientists to analyze whole genomes in one fell swoop, rather than a few hundred genes at a time. Parent company Roche Diagnostics distributes 454 Life Sciences' Genome Sequencing Systems to clinical laboratories, research departments of drugmakers, and other customers worldwide. Research fields include cancer and infectious disease, drug discovery, and paleontology. The company's 454 Sequencing Center provides sequencing services directly.

Morphotek has mighty morphin' power, but don't expect to find its products on the shelves of the local toy store. The biotechnology company develops monoclonal antibody (single-source protein) therapies for the treatment of cancer, inflammation, and infectious diseases using its proprietary Morphogenics technology platform. It conducts research and clinical development programs on its own drug candidates for ailments such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. Morphotek also enters collaborative research partnerships and licenses out its technology to other drug companies such as Amgen and Novo Nordisk. The company is a subsidiary of Eisai Inc., part of Japanese drug firm Eisai.

Insmed Incorporated Company was founded in 1999 and is headquartered in Richmond, Virginia. Insmed Incorporated, a development stage company, engages in the development of recombinant protein drug. The company's primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions, as well as conducting a phase III enabling clinical trial for investigating IPLEX as a treatment for myotonic muscular dystrophy. Insmed also engages in various oncology programs, including INSM-18, an orally available small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF-1 and human epidermal growth factor receptor; and rhIGFBP-3, which is in early clinical development stage for the treatment of breast, prostate, liver, ovarian, and colon cancers. The company also provides Expanded Access Program in Italy to offer IPLEX to physicians for use in their patients with amyotrophic lateral sclerosis. It has a license to Pharmacia AB's portfolio of regulatory filings pertaining to rhIGF; and an agreement with NAPO Pharmaceuticals that gives NAPO the right to develop, manufacture, and commercialize masoprocal products for various indications relating to diabetes, cardiac disease, vascular disease, metabolic disease, and syndrome X.

Lundbeck Inc. (formerly Ovation Pharmaceuticals) hopes to earn its applause by staying on the look-out for niche pharmaceuticals that larger drugmakers cast aside. The company's focus is on developing drugs for central nervous system (CNS) disorders, as well as cancer drugs and hospital-based therapies. Its FDA-approved products for neurological conditions include treatments for ADHD, anxiety, and seizures; the company has several CNS products in its development pipeline, such as epilepsy drugs, drug addiction therapies, and seizure medications. Among its other marketed products are several oncology drugs, as well as a treatment for lead poisoning. The company was acquired by Denmark-based H. Lundbeck in 2009.

meros Corporation was founded in 1994 and is based in Seattle, Washington. Omeros Corporation is a clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company’s clinically advanced product candidates are derived from its PharmacoSurgerytm platform designed to improve the clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Its PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery.

Watson Pharmaceuticals, Inc. was founded in 1983 and is based in Corona, California. Watson Pharmaceuticals, Inc. (Watson) is a specialty pharmaceutical company engaged in the development, manufacture, marketing, sale and distribution of brand and generic (off-patent) pharmaceutical products. Watson operates and manages its business as three operating segments: Generic, Brand and Distribution. As of December 31, 2008, the Company marketed approximately 150 generic pharmaceutical product families and 27 brand pharmaceutical product families through its generic and brand divisions, respectively, and distributed approximately 8,000 stock-keeping units (SKUs) through its distribution division. The Company’s operations are based predominantly in the United States and India, with its key commercial market being the United States. In December 2009, the Company completed the acquisition of Arrow Group. In January 2010, the Company completed the acquisition of Eden Biopharm Group Limited.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.